Pancreatic Cancer Research

ResearcherIstituto Tumori BariActive in the last 2 years

Letizia Porcelli

Matched on ORCID iD 0000-0003-0175-9716; OpenAlex author ID A5029535504. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 9

  1. Integrated single cell RNA sequencing and flow cytometry analysis identifies elevated S100A6+ and S100A8+ myeloid subsets in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.clim.2026.110665↗
  2. Gene Expression Comparison between Alcohol-Exposed versus Not Exposed Pancreatic Ductal Adenocarcinoma Patients Reveals a Peculiar TGFβ-Related Phenotype: An E… First author DOI 10.3390/medicina59050872↗
  3. Microfluidic-Assisted Preparation of Targeted pH-Responsive Polymeric Micelles Improves Gemcitabine Effectiveness in PDAC: In Vitro Insights. Co-author DOI 10.3390/cancers14010005↗
  4. Hydroxy-Propil-β-Cyclodextrin Inclusion Complexes of two Biphenylnicotinamide Derivatives: Formulation and Anti-Proliferative Activity Evaluation in Pancreatic… Co-author DOI 10.3390/ijms21186545↗
  5. Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells. Co-author DOI 10.1038/s41598-019-40637-z↗
  6. CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. Co-author DOI 10.3390/cancers11030330↗
  7. Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Ta… Co-author DOI 10.3390/cancers11070942↗
  8. Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.2147/ott.s106496↗
  9. Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Co-author DOI 10.1016/j.molonc.2012.10.002↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Amalia Azzariti · 9 shared papers, 2013–2026 · strength 1.01
  2. Nicola Silvestris · 8 shared papers, 2013–2026 · strength 0.80
  3. Rosa Maria Iacobazzi · 6 shared papers, 2016–2021 · strength 0.54
  4. Oronzo Brunetti · 4 shared papers, 2016–2026 · strength 0.47
  5. Antonio Giovanni Solimando · 3 shared papers, 2019–2023 · strength 0.39
  6. Antonella Argentiero · 2 shared papers, 2019–2023 · strength 0.30
  7. Riccardo Memeo · 1 shared paper, 2026 · strength 0.23
  8. Afshin Derakhshani · 1 shared paper, 2026 · strength 0.23
  9. Vito Racanelli · 1 shared paper, 2026 · strength 0.23
  10. Mario Testini · 1 shared paper, 2026 · strength 0.23
  11. Adib Miraki Feriz · 1 shared paper, 2026 · strength 0.23
  12. Behzad Baradaran · 1 shared paper, 2026 · strength 0.23
  13. Nunzio Denora · 2 shared papers, 2020–2021 · strength 0.21
  14. Antonio Doronzo · 1 shared paper, 2023 · strength 0.20
  15. Eloisa Sardella · 1 shared paper, 2019 · strength 0.09
  16. Aldo Scarpa · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.